**Earnings Summary for Kymera Therapeutics, Inc. for the Quarter Ended June 30, 2024**

**Earnings Summary for Kymera Therapeutics, Inc. for the Quarter Ended June 30, 2024** Kymera Therapeutics, Inc. (KYMR) has reported its financial results for the quarter ended June 30, 2024. ### Key Financial Metrics | Metric | Q2 2024 | Q1 2024 | Q2 2023 | Consensus Estimates (Q2 2024) | |---------------------------------|-----------------------|-----------------------|-----------------------|-------------------------------| | Total Revenue | $25.7 million | $10.2 million | $16.5 million | $12.55 million | | Earnings per Share (EPS) | -$0.64 | -$1.00 | -$0.65 | -$0.68 | **Interpretation:** Kymera Therapeutics displayed a notable improvement in total revenue for Q2 2024, surpassing both its Q1 2024 revenue and consensus estimates significantly. The company's EPS also beat consensus estimates which reflects better than expected control over costs and financials. ### Stock Price Movement After Earnings Release | Date of Earnings Release | Stock Price Change | |--------------------------|-------------------| | After Event | +4.99% | --- In summary, Kymera Therapeutics, Inc. showcased strong financial performance for the quarter ending June 30, 2024, with revenue and EPS surpassing consensus estimates and displaying growth when compared to both the prior quarter and the same quarter last year. The company's stock price reflected the positive results with a significant increase post-earnings release.